Briefing
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
Extended off-treatment follow-up of CLL14 reporting MRD dynamics after venetoclax-obinutuzumab, including durability of undetectable MRD and its association with outcomes. Level 2.
- Design: paper
- Assay: Peripheral-blood MRD after end of fixed-duration Ven-O